TSLA
Tesla
-- 425.360 NVDA
NVIDIA
-- 137.277 PLTR
Palantir
-- 74.050 AMD
Advanced Micro Devices
-- 130.100 GOOG
Alphabet-C
-- 195.935 
Update
$Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
GlobeNewswire· 12 mins ago
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
GlobeNewswire· 12 mins ago
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment